Matrine
(Synonyms: 苦参碱; Matridin-15-one; Vegard; α-Matrine) 目录号 : GC17874An alkaloid with diverse biological activities
Cas No.:519-02-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
MNK45 gastric cancer cell line |
Preparation method |
Soluble in water, ethanol, chloroform, toluene, and benzene. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
0.05, 0.10, 0.25, and 0.50 mg/ml for 48 h |
Applications |
Matrine showed a dose-dependent inhibition of the growth of MKN45 cells and the concentration needed for 50% inhibition of growth of MKN45 cells was 0.5 mg/ml. It was also found that after matrine treatment at 0.05, 0.1, 0.25, and 0.50 mg/ml, the IKKa, IjBa, IjBb, phospho-IjBa proteins levels in MKN45 cells were significantly higher than those in control cells. In addition, the p-ERK protein expression level in low dose matrine-treated MKN45 cells was significantly higher than that in high dose matrine-treated MKN45 cells. |
Animal experiment [2]: | |
Animal models |
Adult male BALB/c mice |
Dosage form |
25, 50 or 100 mg/kg, i.p. |
Application |
Treatment with matrine could significantly reduce LPS-induced mouse death, the accumulative mortalities during 3 days in high dose of matrine (100 mg/kg) treatment groups (55%) was significantly lower than that in LPS groups (80%). However, no protection was observed when mice received matrine treatment at dose of 25 mg/kg and 50 mg/kg. Matrine treatment could also significantly improve the lung injury, such as pulmonary edema, infiltration of inflammatory cells in the lung tissues and alveoli, and alveolar damage. There was no obvious change in lung structure in control and matrine groups. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Luo C, et al. Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism. Mol Biol Rep. 2012 May;39(5):5459-64. [2]. Zhang B, et al. Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur J Pharm Sci. 2011 Dec 18;44(5):573-9. |
Cas No. | 519-02-8 | SDF | |
别名 | 苦参碱; Matridin-15-one; Vegard; α-Matrine | ||
化学名 | (41S,7aS,13aR,13bR)-dodecahydro-1H-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10(41H)-one | ||
Canonical SMILES | O=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CCC1 | ||
分子式 | C15H24N2O | 分子量 | 248.36 |
溶解度 | ≥ 12.4 mg/mL in DMSO, ≥ 47.2 mg/mL in EtOH, ≥ 50.3 mg/mL in Water with ultrasonic and warming | 储存条件 | Store at 2-8°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.0264 mL | 20.1321 mL | 40.2641 mL |
5 mM | 0.8053 mL | 4.0264 mL | 8.0528 mL |
10 mM | 0.4026 mL | 2.0132 mL | 4.0264 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。